Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA CAR-T cells (Southwest Hospital)
- Development stage
- Unknown
- Lead developer
- Southwest Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This is an investigational anti-carcinoembryonic antigen (anti-CEA) chimeric antigen receptor T-cell (CAR-T) therapy developed by Southwest Hospital of the Third Military Medical University in Chongqing, China. The therapy involves the genetic modification of a patient's autologous T cells to express a CAR targeting CEA (CEACAM5), a cell surface glycoprotein overexpressed in various solid tumors. It was evaluated in a first-in-human Phase 1 clinical trial (NCT02349724) for patients with CEA-positive relapsed or refractory metastatic cancers, including colorectal, gastric, lung, breast, and pancreatic cancers. The treatment aims to induce targeted cell lysis of CEA-expressing malignant cells through the activation of the engineered T cells upon antigen recognition.
- Other names
- CEA-targeted CAR-T cellsanti-CEA chimeric antigen receptor T cellsanti-carcinoembryonic antigen chimeric antigen receptor T cells
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on anti-CEA CAR-T cells (Southwest Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA CAR-T cells (Southwest Hospital).